| 组蛋白去乙酰化酶抑制剂在外周T细胞淋巴瘤中的应用进展 |
| |
| 引用本文： | 杨明子,刘卫平,朱军. 组蛋白去乙酰化酶抑制剂在外周T细胞淋巴瘤中的应用进展[J]. 中国肿瘤临床, 2018, 45(13): 653-656. DOI: 10.3969/j.issn.1000-8179.2018.13.235 |
| |
| 作者姓名： | 杨明子 刘卫平 朱军 |
| |
| 作者单位： | 北京大学肿瘤医院暨北京市肿瘤防治研究所淋巴肿瘤内科，恶性肿瘤发病机制及转化研究教育部重点实验室（北京市100142） |
| |
| 基金项目： | 首都卫生发展科研专项2018-1-2151CSCO-齐鲁肿瘤研究基金项目Y-Q2017-035北京市医院管理局“登峰”人才计划培养项目DFL20151001 |
| |
| 摘 要： | 外周T细胞淋巴瘤（peripheralTcelllymphoma，PTCL）是一类具有高度异质性的起源于成熟T细胞或NK细胞的恶性肿瘤，大多数类型侵袭性高、进展快，总体预后不佳。表观遗传修饰对PTCL在内的恶性肿瘤的发生发展起重要作用。目前与表观遗传调控相关的组蛋白去乙酰化酶抑制剂（histonedeacetylaseinhibitors，HDACi）已经用于PTCL的治疗，在单药及联合治疗时显示出良好的耐受性和治疗效果，其中伏立诺他、罗米地辛、贝利司他和西达本胺已先后被批准上市。本文对HDACi在PTCL治疗方面的应用进展进行综述。
|
| 关 键 词： | 表观遗传学 组蛋白去乙酰化酶抑制剂 外周T细胞淋巴瘤 治疗 |
| 收稿时间： | 2018-03-09 |
Advances in histone deacetylase inhibitors for the treatment of peripheral T-cell lymphoma |
| |
| Affiliation: | Department of Lymphoma, Beijing Cancer Hospital, Peking University School of Clinical Oncology, Beijing Institute for Cancer Research, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China |
| |
| Abstract: | Peripheral T-cell lymphoma (PTCL) is a group of highly heterogeneous non-Hodgkin's lymphomas derived from mature T or NK cells. Most subtypes of PTCL are highly aggressive with rapid growth and poor prognosis. Recently, epigenetic modification has been reported to play an important role in the evolution and progression of cancers, especially PTCL. Therefore, as a novel antineoplastic agent, histone deacetylase inhibitor has already been used in treating PTCL. The histone deacetylase inhibitor with or without chemotherapy or other therapies showed good tolerance and significant efficacy. Several histone deacetylase inhibitors, such as vorinostat, romidepsin, belinostat, and chidamide, have been approved by the FDA or CFDA. This review summarizes the advances of using histone deacetylase inhibitors as an alternative anti-cancer therapeutic strategy for the treatment of PTCL. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
